Trial Profile
A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms BAYOU
- Sponsors AstraZeneca
- 13 Nov 2023 Planned End Date changed from 4 Sep 2023 to 31 Dec 2024.
- 22 Jul 2022 This trial has been completed in Spain(End date:2020-10-15), according to European Clinical Trials Database record.
- 23 Jun 2022 Results published in the Journal of Clinical Oncology